Today's Rundown Featured Story | | | Wednesday, February 6, 2019 GlaxoSmithKline is cutting a host of unwanted investigational drugs as it joins other Big Pharmas in the fourth-quarter clearout. |
|
|
Top Stories Wednesday, February 6, 2019 The Big Pharma has culled a pair of phase 2 assets—a dual amylin calcitonin receptor agonist for the treatment of diabetes and a BTK inhibitor being investigated in immunology—as well as a urocortin-2 peptide treatment for heart failure that had reached phase 1. Wednesday, February 6, 2019 Genentech has paid $120 million upfront to secure global rights to IL-15 cytokine therapeutics in preclinical development at Xencor. The upfront sets the Roche subsidiary up to incorporate the candidates into its immuno-oncology combination strategy. Wednesday, February 6, 2019 A phase 3 trial of MacroGenics’ margetuximab in HER2-positive metastatic breast cancer patients has met its primary endpoint. The anti-HER2 antibody improved progression-free survival by more than Herceptin, teeing MacroGenics up to file for approval in the second half of the year. Wednesday, February 6, 2019 The Cambridge, Massachusetts-based biotech announced updated data on Wednesday for two trials of its lentiviral-based, ex vivo gene therapy in patients who had previously received enzyme replacement therapy and patients who hadn't. Wednesday, February 6, 2019 The ubiquitous messaging company Slack has confidentially filed for an IPO—except not-so-confidentially, as it went public with the news on its own earlier this week with a press release. | This week's sponsor is Camargo. | |  | [Webinar] Maximizing the Value of Your Drug Development Program
Thursday, February 21 | 11am ET / 8am PT
This webinar will benefit executives at Biotech and Pharmaceutical companies interested in learning more about 505(b)(2) drug development and how to save time and money while maximizing the value of their drug development program. Register Now! |
Enrollment Showcase | | | Sponsored by: Drexel University Online Drexel University’s online graduate programs in biomedicine, clinical research, drug discovery, and molecular medicine were developed with working professionals in mind, providing you with the education, practical skills, and competitive edge you need to be successful in your career. Learn more. |
|
|
Resources Sponsored by: Patheon, part of Thermo Fisher Scientific When a biologics company prepares to launch a new product, it must forecast the manufacturing capacity it will need, factoring in its estimate of the size of future sales, the timing of the launch, the dosage of the product, its strategy for building its market and a host of other variables. Sponsored by: Oracle Health Sciences 92% of survey respondents make changes to their RTSM/IRT systems due to study changes. See what else puts a strain on their clinical trials. Download the Research Whitepaper. Sponsored by: Patheon, part of Thermo Fisher Scientific Download this whitepaper to learn more. Sponsored by: The Kinetix Group Explore how the pharma industry can adapt its approach to the changing healthcare marketplace in the era of the Quadruple Aim Sponsored by: Cofactor Genomics Learn how Health Expression Models provide increased sensitivity, specificity, and accuracy for characterizing immune response in solid tumor specimens. Sponsored by: BioAnalytix, Inc. This whitepaper reviews fundamental aspects of HCPs that pertain to biologic drug development and presents current and emerging approaches to HCP analysis. Sponsored by: Veradigm Clinical trials take too long and cost too much—here's what needs to change. Sponsored by: AlphaSense It’s never been more challenging to stay on top of competitive factors impacting your industry. Discover how AI can help competitive teams achieve more proactive market intelligence. Sponsored by: Reprints Desk, Inc. Go from Search to Full-Text Scientific Papers in a Single Click! Sponsored by: Blue Latitude Health This white paper consists of original data and expert interviews. Download it today for exclusive tools, tips and analysis on achieving launch excellence in challenging pharma markets. Sponsored by: Outer Edge Technology With FDA approval imminent, start-up Life Sciences company partners with an industry focused MSP to design and manage its regulated cloud-based infrastructure to speed time to market. Sponsored by: DeciBio Consulting With the liquid biopsy market maturing and >80 companies still competing with liquid biopsy offerings, it is crucial for investors to be able to cut through the noise and identify the winners. Presented by: Veeva Share your thoughts on the life sciences industry's progress in improving study execution. Sponsored by: Biotech Primer The Biopharma industry is moving at lightning speed and it can be a challenge to keep pace. Here at Biotech Primer we spend hours each week researching, writing, and editing original content for the Biotech Primer WEEKLY with one goal in mind: to help everyone better understand the latest science and technology driving today’s healthcare industry. | 
